NEWRON PHARMACEUT. EO-20 Asset Resilience Ratio
NEWRON PHARMACEUT. EO-20 asset resilience ratio. NEWRON PHARMACEUT. EO-20 (NP5) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NP5 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NEWRON PHARMACEUT. EO-20 (2009–2025)
Asset resilience ratio of NEWRON PHARMACEUT. EO-20 from 2009 to 2025. This chart shows how NEWRON PHARMACEUT. EO-20's Asset Resilience Ratio has changed over time. Read NEWRON PHARMACEUT. EO-20 (NP5) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NEWRON PHARMACEUT. EO-20's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NP5 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €16.68 Million | 41.67% |
| Total Liquid Assets | €16.68 Million | 41.67% |
Asset Resilience Insights
- Very High Liquidity: NEWRON PHARMACEUT. EO-20 maintains exceptional liquid asset reserves at 41.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NEWRON PHARMACEUT. EO-20 Industry Peers by Asset Resilience Ratio
Compare NEWRON PHARMACEUT. EO-20's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
NEWRON PHARMACEUT. EO-20 Asset Resilience Ratio by Year (2009–2025)
NEWRON PHARMACEUT. EO-20 asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for NEWRON PHARMACEUT. EO-20.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.67% | €16.68 Million ≈ $19.50 Million |
€40.03 Million ≈ $46.80 Million |
+37.14pp |
| 2024-12-31 | 4.53% | €2.89 Million ≈ $3.38 Million |
€63.91 Million ≈ $74.72 Million |
-19.68pp |
| 2023-12-31 | 24.21% | €6.26 Million ≈ $7.32 Million |
€25.87 Million ≈ $30.24 Million |
-0.93pp |
| 2022-12-31 | 25.14% | €9.35 Million ≈ $10.93 Million |
€37.20 Million ≈ $43.48 Million |
+6.17pp |
| 2021-12-31 | 18.97% | €9.57 Million ≈ $11.19 Million |
€50.49 Million ≈ $59.02 Million |
-16.26pp |
| 2020-12-31 | 35.23% | €18.04 Million ≈ $21.09 Million |
€51.20 Million ≈ $59.86 Million |
+6.85pp |
| 2019-12-31 | 28.38% | €17.11 Million ≈ $20.00 Million |
€60.29 Million ≈ $70.48 Million |
+1.33pp |
| 2018-12-31 | 27.05% | €16.23 Million ≈ $18.97 Million |
€60.00 Million ≈ $70.15 Million |
+0.43pp |
| 2017-12-31 | 26.62% | €19.44 Million ≈ $22.73 Million |
€73.02 Million ≈ $85.37 Million |
+20.40pp |
| 2016-12-31 | 6.22% | €3.52 Million ≈ $4.12 Million |
€56.59 Million ≈ $66.16 Million |
-4.87pp |
| 2015-12-31 | 11.09% | €4.92 Million ≈ $5.75 Million |
€44.38 Million ≈ $51.88 Million |
-7.65pp |
| 2014-12-31 | 18.74% | €6.95 Million ≈ $8.12 Million |
€37.07 Million ≈ $43.34 Million |
+1.48pp |
| 2013-12-31 | 17.26% | €5.46 Million ≈ $6.38 Million |
€31.62 Million ≈ $36.96 Million |
+9.10pp |
| 2012-12-31 | 8.16% | €3.64 Million ≈ $4.26 Million |
€44.65 Million ≈ $52.20 Million |
+4.30pp |
| 2009-12-31 | 3.85% | €1.60 Million ≈ $1.88 Million |
€41.68 Million ≈ $48.73 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more